Coagulation factor IXa (FIXa) (within the intrinsic tenase complex) (FIXa)

Coagulation factor IXa (FIXa) is the activated form of Factor IX, a vitamin K-dependent serine protease essential for the intrinsic pathway of blood coagulation [5, 8]. Within the intrinsic tenase complex, Factor IXa associates with its cofactor, Factor VIIIa, on a phospholipid surface in the presence of calcium ions to catalyze the conversion of Factor X to Factor Xa [1, 13]. This step represents a critical amplification point in the coagulation cascade, as the tenase complex is significantly more efficient at activating Factor X than Factor IXa alone [8, 12]. Deficiencies in Factor IX lead to Hemophilia B, a hereditary bleeding disorder characterized by spontaneous or prolonged bleeding [8, 15]. Conversely, Factor IXa is a therapeutic target for anticoagulation; its inhibition can prevent thrombus formation with a potentially lower risk of bleeding compared to traditional anticoagulants like warfarin or direct thrombin inhibitors [3, 9, 12]. Drugs targeting FIXa include indirect inhibitors like heparin and direct inhibitors such as RNA aptamers and monoclonal antibodies currently in clinical development [7, 12]. The unique structural features of FIXa, including its partially collapsed active site and reliance on exosites for cofactor binding, provide opportunities for highly specific drug design [3, 15]. Monitoring the efficacy of FIXa-targeted therapies typically involves measuring the activated partial thromboplastin time (aPTT) or specific FIXa activity levels [9].

Other names

Factor IXaActivated factor IXChristmas factor activatedPlasma thromboplastin component activatedF9aSerine protease FIXaIntrinsic tenase complex

Inhibition of the enzymatic activity of Factor IXa through direct active site blocking, allosteric modulation via exosite binding, or disruption of the assembly with its cofactor Factor VIIIa within the intrinsic tenase complex.